Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move the drug into ...
Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table summarizes their recent ratings, shedding light on the ...
Years after the launch of a controversial Alzheimer’s drug nearly crippled the company, Biogen is moving an experimental treatment into late-stage trials. Wall Street is not yet sold. The biotech on ...
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose-response data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results